Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ATHA - Athira Pharma, Inc.


IEX Last Trade
0.5447
0.074   13.604%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:00 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.82%

PREVIOUS CLOSE
CHG
CHG%

$0.47
0.07
15.75%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-5.90%
1 Month
-13.63%
3 Months
24.06%
6 Months
-75.25%
1 Year
-74.91%
2 Year
-81.81%
Key data
Stock price
$0.54
P/E Ratio 
0.00
DAY RANGE
$0.47 - $0.55
EPS 
$0.00
52 WEEK RANGE
$0.42 - $4.30
52 WEEK CHANGE
-$76.54
MARKET CAP 
118.778 M
YIELD 
N/A
SHARES OUTSTANDING 
38.439 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.17
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$293,241
AVERAGE 30 VOLUME 
$327,510
Company detail
CEO: Mark J. Litton
Region: US
Website: athira.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in Phase 3 and ACT-AD clinical trials for the treatment of Alzheimer's disease.

Recent news